Zabalafin Hydrogel: A Breakthrough for Atopic Dermatitis
Atopic dermatitis (AD) is a chronic skin condition that impacts millions of people, causing itching, inflammation, and bacterial infections. Alphyn Biologics, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, has announced a significant advancement in the treatment of AD with the FDA's approval of its Investigational New Drug Application for Zabalafin Hydrogel. This treatment is [...]
